Resource data sheet
Prev.

pENTER-EGFR Del19

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-activating mutation.

Catalog number RDB15489
Resource name pENTER-EGFR Del19
Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, deletion in exon 19, EGFR-activating mutation.
cDNA was obtained from HCC-827 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor Katayama, Ryohei |
 
Other clones in our bank human EGFR (NCBI Gene 1956) |

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Terms and conditions set forth by the DEPOSITOR In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Ordering Please visit Information of Request for Distribution. 
Order form [Credit Card Payment]  [Bank Transfer or Check Payment]
Material Transfer Agreement (MTA) [Word]
Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
Distribution information (domestic users) [open/close]


Catalog # Resource name Availability Shipping form Fee (non-profit org.)
RDB15489 pENTER-EGFR Del19 Under QC test. Please contact us. DNA solution

Ordering Information [in Japanese] [in English]

References and tips

Electronic file

Original reference

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

Further references such as user reports and related articles (go to bottom)

Featured content

Sequence information

This clone will be sequenced a portion and digested by restriction enzyme for examination.

References

Original, user report and related articles

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

2019.07.17

GNP_filter3_RDBDEP_html_190432.pl